Helen A Mintz-Hittner

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. pmc Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy
    Helen A Mintz-Hittner
    Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center at Houston UTHealth McGovern Medical School, Houston, Texas W T and Louise J Moran Pediatric Eye Clinic, Robert Cizik Eye Clinic, Houston, Texas Electronic address
    Ophthalmology 123:1845-55. 2016
  2. doi Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center, Houston Medical School, 6400 Fannin Street, Suite 1800, Houston, TX 77030 1526, USA
    Early Hum Dev 88:937-41. 2012
  3. doi Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial
    Helen A Mintz-Hittner
    Robert Cizik Eye Center, University of Texas Health Science Center at Houston Medical School, Department of Ophthalmology and Visual Science, Houston, TX 77030, USA
    Eur J Ophthalmol 22:685-6. 2012
  4. pmc Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center at Houston Medical School, Houston, USA
    N Engl J Med 364:603-15. 2011
  5. doi Antivascular endothelial growth factor for retinopathy of prematurity
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center, Houston University of Texas Houston Medical School, 6410 Fannin St, Houston, TX 77030 5204, USA
    Curr Opin Pediatr 21:182-7. 2009
  6. ncbi Successful amblyopia therapy initiated after age 7 years: compliance cures
    H A Mintz-Hittner
    Department of Opthalmology and Visual Science, University of Texas Houston Medical School, USA
    Arch Ophthalmol 118:1535-41. 2000
  7. doi Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center Houston Medical School, Houston, TX 77030, USA
    Retina 28:831-8. 2008
  8. ncbi VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Houston Medical School, 6410 Fannin, Suite 920, Houston, TX 77030 5204, USA
    Ophthalmology 111:828-36. 2004
  9. ncbi Laser in situ keratomileusis for treated anisometropic amblyopia in awake, autofixating pediatric and adolescent patients
    Christopher B Phillips
    Department of Ophthalmology and Visual Science, University of Texas Houston Medical School, Houston, Texas, USA
    J Cataract Refract Surg 30:2522-8. 2004
  10. doi Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial
    Megan M Geloneck
    Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center Houston Medical School, Houston
    JAMA Ophthalmol 132:1327-33. 2014

Collaborators

Detail Information

Publications13

  1. pmc Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy
    Helen A Mintz-Hittner
    Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center at Houston UTHealth McGovern Medical School, Houston, Texas W T and Louise J Moran Pediatric Eye Clinic, Robert Cizik Eye Clinic, Houston, Texas Electronic address
    Ophthalmology 123:1845-55. 2016
    ..To determine incidence, risk factors, risk period, and characteristics of recurrent retinopathy of prematurity (ROP) treated by intravitreal bevacizumab (IVB) monotherapy...
  2. doi Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center, Houston Medical School, 6400 Fannin Street, Suite 1800, Houston, TX 77030 1526, USA
    Early Hum Dev 88:937-41. 2012
    ..The benefits have been demonstrated, however, local and systemic risks in these developing premature infants must be carefully studied (both short and long term)...
  3. doi Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial
    Helen A Mintz-Hittner
    Robert Cizik Eye Center, University of Texas Health Science Center at Houston Medical School, Department of Ophthalmology and Visual Science, Houston, TX 77030, USA
    Eur J Ophthalmol 22:685-6. 2012
    ..Both intravitreal pegaptanib with laser therapy and intravitreal bevacizumab monotherapy have been found to be more efficacious than laser therapy alone in prospective, randomized, controlled clinical trials...
  4. pmc Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center at Houston Medical School, Houston, USA
    N Engl J Med 364:603-15. 2011
    ..Case series in which patients were treated with vascular endothelial growth factor inhibitors suggest that these agents may be useful in treating retinopathy of prematurity...
  5. doi Antivascular endothelial growth factor for retinopathy of prematurity
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center, Houston University of Texas Houston Medical School, 6410 Fannin St, Houston, TX 77030 5204, USA
    Curr Opin Pediatr 21:182-7. 2009
    ..Avastin (bevacizumab) therapy is a promising anti-vascular endothelial growth factor (anti-VEGF) administered directly into the vitreous...
  6. ncbi Successful amblyopia therapy initiated after age 7 years: compliance cures
    H A Mintz-Hittner
    Department of Opthalmology and Visual Science, University of Texas Houston Medical School, USA
    Arch Ophthalmol 118:1535-41. 2000
    ..To report successful therapy for anisometropic and strabismic amblyopia initiated after age 7 years...
  7. doi Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Health Science Center Houston Medical School, Houston, TX 77030, USA
    Retina 28:831-8. 2008
    ..South San Francisco, CA)...
  8. ncbi VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells
    Helen A Mintz-Hittner
    Department of Ophthalmology and Visual Science, University of Texas Houston Medical School, 6410 Fannin, Suite 920, Houston, TX 77030 5204, USA
    Ophthalmology 111:828-36. 2004
    ..To present a previously unreported African American family with 1 variation and 1 mutation of the homeobox transcription factor gene, VSX1 (RINX), and to describe the clinical features of family members...
  9. ncbi Laser in situ keratomileusis for treated anisometropic amblyopia in awake, autofixating pediatric and adolescent patients
    Christopher B Phillips
    Department of Ophthalmology and Visual Science, University of Texas Houston Medical School, Houston, Texas, USA
    J Cataract Refract Surg 30:2522-8. 2004
    ..To establish the safety and efficacy of laser in situ keratomileusis (LASIK) in pediatric and adolescent patients with anisometropic amblyopia who completed amblyopia therapy and had a visual acuity of 20/30 or better bilaterally...
  10. doi Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial
    Megan M Geloneck
    Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center Houston Medical School, Houston
    JAMA Ophthalmol 132:1327-33. 2014
    ..Children born prematurely who develop retinopathy of prematurity (ROP) often develop myopia, and those who require laser treatment may develop very high myopia, which has considerable clinical consequences...
  11. ncbi Laser in situ keratomileusis for high hyperopia in awake, autofixating pediatric and adolescent patients with fully or partially accommodative esotropia
    Christopher B Phillips
    Department of Ophthalmology and Visual Science, The University of Texas Houston Medical School, Houston, TX, USA
    J Cataract Refract Surg 30:2124-9. 2004
    ..To establish the safety and efficacy of laser in situ keratomileusis (LASIK) in pediatric and adolescent patients with bilateral visual acuity of 20/30 or better and accommodative or partially accommodative esotropia...
  12. ncbi Microcornea and subluxated lenses due to a splicing error in the fibrillin-1 gene in a patient with Marfan syndrome
    Mark C Vital
    University of Texas Houston Medical School, Department of Ophthamology and Visual Science, Houston, Tex 77030 5204, USA
    Arch Ophthalmol 121:579-81. 2003
  13. doi Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study
    Lingkun Kong
    Arch Ophthalmol 126:1161-3. 2008